Drugs / Dolutegravir / Lamivudine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04585737 | Oct 2020 → Aug 2023 | HIV infectious disease | Charlotte-Paige Rolle, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dolutegravir / Lamivudine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04585737 ↗ |
| Route | Oral | “administered orally” NCT04585737 ↗ |